Contents 2 min read

Claim and source comparison

CDP-choline: the ICTUS stroke trial, radiolabelled human pharmacokinetics and the EFSA memory assessment.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

ICTUS (2012) compared citicoline with placebo in 2298 people with moderate-to-severe acute ischemic stroke. Global recovery at day 90 after six weeks of treatment was similar (OR 1.03; 95% CI 0.86–1.25); the trial stopped for futility.

This hospital trial did not study memory enhancement in healthy people. Similar adverse-event rates do not establish long-term or combination safety. Funding came from Ferrer Grupo.

Source 3 · Abstract read

Human pharmacokinetic study

Dinsdale et al. (1983) reported two plasma-radioactivity peaks at 1 and 24 hours after 300 mg radiolabelled citicoline in 6 healthy adults. Respiratory and urinary elimination were biphasic.

Elimination of radioactivity and metabolites is not the plasma half-life of unchanged citicoline. This small study does not validate a one-compartment decay curve or personal intake times.

Source 5 · Abstract read

Regulatory scientific assessment

EFSA (2024) concluded that a cause-and-effect relationship was not established between citicoline and improvement, maintenance or reduced loss of memory in middle-aged and older adults with age-associated subjective memory complaints.

The single positive 12-week trial at 500 mg/day was not corroborated by other data; convincing human-mechanism evidence was not supplied. This health-claim assessment is not product safety approval.

Source 6 · Official summary read

Our evidence and source methodology

CDP-Choline: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is CDP-Choline?

CDP-choline is a choline and nucleotide precursor. It has been examined in some memory studies; dopamine receptor findings are animal data and do not establish improved motivation in healthy people.

Mechanism of Effect

Dinsdale et al. (1983) reported two plasma-radioactivity peaks at 1 and 24 hours after 300 mg radiolabelled citicoline in 6 healthy adults. Respiratory and urinary elimination were biphasic.

Elimination of radioactivity and metabolites is not the plasma half-life of unchanged citicoline. This small study does not validate a one-compartment decay curve or personal intake times.

Clinical Evidence

ICTUS (2012) compared citicoline with placebo in 2298 people with moderate-to-severe acute ischemic stroke. Global recovery at day 90 after six weeks of treatment was similar (OR 1.03; 95% CI 0.86–1.25); the trial stopped for futility.

This hospital trial did not study memory enhancement in healthy people. Similar adverse-event rates do not establish long-term or combination safety. Funding came from Ferrer Grupo.

EFSA (2024) concluded that a cause-and-effect relationship was not established between citicoline and improvement, maintenance or reduced loss of memory in middle-aged and older adults with age-associated subjective memory complaints.

The single positive 12-week trial at 500 mg/day was not corroborated by other data; convincing human-mechanism evidence was not supplied. This health-claim assessment is not product safety approval.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

These sources do not determine long-term or combination safety of CDP-choline in healthy people. Similar adverse-event rates in a stroke trial are not general safety approval.

Sources

  1. Secades JJ. (2011). Citicoline: pharmacological and clinical review, 2010 update. Revista de Neurología, 52(Suppl 2), S1–S62. PubMed · PMID 21432836
  2. Alvarez-Sabín J, Román GC. (2013). The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sciences, 3(3), 1395–1414. PubMed · PMID 24961534
  3. Dávalos A, et al. (2012). Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). The Lancet, 380(9839), 349–357. PubMed · PMID 22691567
  4. Fioravanti M, Buckley AE. (2006). Citicoline (Cognizin) in the treatment of cognitive impairment. Clinical Interventions in Aging, 1(3), 247–251. PubMed · PMID 18046877
  5. Dinsdale JR, et al. (1983). Pharmacokinetics of 14C CDP-choline. Arzneimittel-Forschung, 33(7A), 1066–1070. PubMed · PMID 6412727
  6. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). (2024). Citicoline and support of the memory function: Evaluation of a health claim. https://www.efsa.europa.eu/en/efsajournal/pub/8861 European Food Safety Authority

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions